NeuroOne Medical Technologies
NMTC
3 hedge funds and large institutions have $2.73M invested in NeuroOne Medical Technologies in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.57% more ownership
Funds ownership: 0% → 0.57% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Mayo Clinic
Rochester,
Minnesota
|
+$1.28M |
| 2 |
BAAM
Baker Avenue Asset Management
San Francisco,
California
|
+$1.26M |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
+$352K |
Top Sellers
NMTC Hedge Fund Activity: Q2 2021 in Review
3 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q2 2021, worth a combined $2.73M.
Buyers outnumbered sellers: 3 funds opened new NMTC positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Mayo Clinic, opening a new position worth an estimated $1.28M.
- 3 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $2.73M of NeuroOne Medical Technologies stock for Q2 2021.
- 3 funds opened new NeuroOne Medical Technologies positions in Q2 2021 and 0 closed out, a net change of +3 holders.
- The largest NeuroOne Medical Technologies buyer in Q2 2021 was Mayo Clinic, an estimated $1.28M added.
Based on aggregated 13F filings for Q2 2021.